|
|
 | | | |
- close
- close
- close
- close
| |||||||||
CAS Medical Systems 10-Q 2009 UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 10-Q
Quarterly Report Pursuant to Section 13 or 15 (d)
of the Securities Exchange Act of 1934
For the Quarterly Period Ended June 30, 2009
Commission File Number 0-13839
CAS MEDICAL SYSTEMS, INC.
(Exact name of registrant as specified in its charter)
44 East Industrial Road, Branford, Connecticut 06405
(Address of principal executive offices, including zip code)
(203) 488-6056
(Registrant’s telephone number, including area code)
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for
the past 90 days. Yes x No o
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Date File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such
files). Yes o No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check
one):
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: Common Stock, $.004 par value 11,519,189 shares as of
August 10, 2009.
Form 10-Q
June 30, 2009
Page 2 INDEX
Form 10-Q
June 30, 2009
Page 3 PART I – FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
CAS Medical Systems, Inc.
Condensed Consolidated Balance Sheets
(Unaudited)
Form 10-Q
June 30, 2009
Page 4 CAS Medical Systems, Inc.
Condensed Consolidated Balance Sheets
(Unaudited)
See accompanying notes.
Form 10-Q
June 30, 2009
Page 5 CAS Medical Systems, Inc.
Condensed Consolidated Statements of Operations
(Unaudited)
See accompanying notes.
Form 10-Q
June 30, 2009
Page 6 CAS Medical Systems, Inc.
Condensed Consolidated Statements of Cash Flows
(Unaudited)
See accompanying notes.
Form 10-Q
June 30, 2009
Page 7 CAS Medical Systems, Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
June 30, 2009
CAS Medical Systems, Inc. (“CAS”) and its wholly-owned subsidiary, Statcorp, Inc. (“Statcorp”) operate as one reportable business segment. Together, CAS and Statcorp (collectively, the “Company” or “CASMED”) develop, manufacture
and distribute diagnostic equipment and medical products for use in the healthcare and medical industry. These products – specifically blood pressure measurement technology, vital signs measurement equipment, cardio-respiratory monitoring equipment, cerebral oximetry monitoring, and supplies for neonatal intensive care - are sold by CASMED through its own sales force, via distributors, manufacturers representatives and pursuant to original equipment manufacturer agreements both internationally and in the
United States. The Company has several other products in various stages of development that it believes will add to and complement its current product lines.
The financial statements included herein have been prepared, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and disclosures included in financial statements prepared in accordance with accounting
principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations. These condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in the Company’s Annual Report filed on Form 10-K for the year ended December 31, 2008. The condensed consolidated balance sheet as of December 31, 2008 was derived from the audited financial statements for the year
then ended.
In the opinion of the Company, all adjustments (consisting of normal recurring accruals) necessary to present fairly the financial position of the Company and the results of its operations and its cash flows have been included in the accompanying financial statements. The
results of operations for interim periods are not necessarily indicative of the expected results for the full year.
The Company has performed a review of events subsequent to the balance sheet date through August 12, 2009, the date the financial statements were issued.
Inventories are stated at the lower of cost or market on a first-in, first-out (FIFO) basis. Inventories consisted of:
Property and equipment are stated at cost. The Company has separately reported its Fore-sight® cerebral oximetry monitors located at customer sites within the United States. Such equipment is held under a no cost program whereby customers purchase disposable sensors
for use with the Company’s equipment. The Company retains title to the monitors shipped to its customers under this program. The monitors are depreciated on a straight-line basis over five years to cost of sales. As of June 30, 2009, the Company has capitalized $1,171,217 of costs pertaining to the monitors which have a net book value of $834,075. Other property and equipment is depreciated using the straight-line method over the estimated useful lives of the assets.
Form 10-Q
June 30, 2009
Page 8 Intangible assets consist of patents issued, patents pending, trademarks, purchased technology and other deferred charges which are recorded at cost. Patents are amortized on a straight-line basis over 1 to 20 years. Costs associated with the development of new external use software products are expensed as incurred until technological
feasibility has been established in accordance with SFAS No. 86 “Accounting for the Costs of Computer Software to be Sold, Leased or Otherwise Marketed.” Technological feasibility is demonstrated by the completion of a detailed design plan. Capitalization ceases when the product is available for general release to customers. Capitalized costs are amortized over their estimated useful lives. Deferred financing costs are amortized over the term of the related debt. Other deferred charges
are amortized over their estimated useful lives.
The Company reviews its long-lived assets including goodwill for impairment at least annually or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company believes that the carrying amounts of its long-lived
assets are fully recoverable.
The Company has categorized its sales of products and services into the following categories:
A summary of the denominators used to compute basic and diluted loss per share follows:
Form 10-Q
June 30, 2009
Page 9 Diluted common stock equivalents such as restricted shares, outstanding warrants and options are excluded from the computation of diluted earnings per share where there is a loss as their inclusion would be anti-dilutive.
Stock compensation expense was $88,749 and $90,822, and $166,417 and $231,315, for the three-month and six-month periods ended June 30, 2009 and 2008, respectively.
As of June 30, 2009, the unrecognized stock-based compensation cost related to non-vested restricted stock and stock option awards was $754,368. Such amount, before estimated forfeitures, will be recognized in operations over a weighted average period of 1.9 years.
The following table summarizes the Company’s stock option information as of, and for the six-month period ended June 30, 2009:
(1) The intrinsic value of a stock option is the amount by which the current market value of the underlying stock as of June 30, 2009 exceeds the option exercise price.
The exercise period for all outstanding stock options may not exceed ten years from the date of grant. Stock options granted to employees and non-employee directors vest ratably typically not less than two years from the grant date. The Company attributes stock-based compensation cost to
operations using the straight-line method over the applicable vesting period.
During the first six months of 2009, non-qualified stock options to purchase an aggregate of 5,000 shares of common stock were granted to a new employee. The stock option vests one-third per year over three years from the grant date.
The weighted-average grant date fair value of stock options granted during the six-month period ended June 30, 2009 and 2008 was $0.82 and $3.92 per share, respectively.
The fair value of each option granted was estimated on the date of grant using the Black-Scholes option-pricing model with the following assumptions:
Form 10-Q
June 30, 2009
Page 10 No stock options were exercised for 2009 during the six months ended June 30, 2009. The total intrinsic value of stock options exercised during the six-month period ended June 30, 2008 was $55,981.
During June 2009, the Company issued as aggregate of 173,528 shares of restricted common stock under the 2003 Equity Incentive Plan to employees and outside members of the Board of Directors. Of the total amount granted, 150,000 shares were issued to employees of which 140,000 shares vest
one-third per year over three years and 10,000 shares vest one-half per year over a two-year period. The 23,528 shares of restricted common stock granted to outside directors vest quarterly over twelve months from the grant date.
On June 10, 2009, the Company’s stockholders approved the CAS Medical Systems, Inc. Employee Stock Purchase Plan. Accordingly, 150,000 shares of common stock have been reserved for issuance under the Stock Purchase Plan. The initial offering period began on July
1, 2009. The Stock Purchase Plan offers the Company’s employees an opportunity to participate in a payroll-deduction based program designed to incentivize them to contribute to the Company’s success and prosperity. The plan approved by the stockholders during June 2009 replaces a plan in effect since June 2004. As of June 30, 2009, 141,218 of the 150,000 shares under the previous plan were issued or reserved to issue and 8,782 shares were cancelled. The current plan contains certain changes
including a reduction of the discount under which participants purchase shares of the Company’s common stock.
On June 10, 2009, the Company’s stockholders also approved an amendment to the CAS Medical Systems, Inc. 2003 Equity Incentive Plan (the “Plan”) which increases the maximum number of shares that can be issued under
the Plan by 250,000 to 1,250,000. Awards that may be granted under the Plan include options, restricted stock and restricted stock units, and other stock-based awards. The purposes of the Plan are to make available to our key employees and directors, certain compensatory arrangements related to growth in value of our stock so as to generate an increased incentive to contribute to the Company’s financial success and prosperity; to enhance the Company’s ability to attract and retain exceptionally qualified
individuals whose efforts can affect the Company’s financial growth and profitability; and align in general the interests of our employees and directors with the interest of our stockholders. As of June 30, 2009, 286,523 shares remain available for issuance under the Plan.
The Company has a line of credit agreement with its bank lender, NewAlliance Bank, which was amended on April 3, 2009 effective March 31, 2009 pursuant to a Second Modification Agreement (as amended, the “Agreement”). In accordance with the Second Modification Agreement, the maximum
availability was modified from $10,000,000 to $5,000,000 subject to a borrowing base formula equal to the sum of (i) 75% of eligible receivables and (ii) the lesser of $2,500,000 or 30% of eligible inventory. Interest on outstanding amounts is at the Prime Rate plus 1.0% and is subject to a floor of 4.0%. Borrowings are secured by a first priority lien on all the business assets of the Company. The Agreement contains customary non-financial covenants and financial covenants, consisting of a debt service coverage
ratio and a debt to tangible net worth ratio, and expires on July 1, 2010. Under the terms of the Agreement, the debt service coverage ratio was revised from a quarterly test to an annual test for the twelve months ending December 31, 2009 and the minimum ratio revised from 1.5 to 1 to 1.0 to 1. As of the first quarter of 2010 and thereafter, the ratio returns to 1.5 to 1 with testing resumed on a quarterly basis. As of June 30, 2009, there was $3,123,277 outstanding under the Agreement.
The Company also has a note payable to NewAlliance Bank which provides for monthly installments of $61,533, including interest at 6%, until May 2012. The balance under that loan at June 30, 2009 was $2,019,786.
During May 2009, the Company entered into a note payable for the financing of certain insurance coverage. A total of $228,052 was financed at 5.2% and is payable at $25,339 per month including interest through February 2010.
Form 10-Q
June 30, 2009
Page 11
The income tax benefits recognized in operations for the periods presented vary from the statutory rate as a result of anticipated state and federal R&D tax credits partially offset by non-deductible stock compensation expense.
Recoverable income taxes consist of estimated state and federal tax refunds generated from the carry back of net operating losses and exchanges of state tax credits for reduced cash receipts payable to the Company.
On May 8, 2007, the Company signed an exclusive distribution agreement (the “Agreement”) with Analogic Corporation (“Analogic”) under which the Company obtained worldwide exclusive rights to market the Analogic Lifegard® family of non-invasive
patient monitors. Under the Agreement, Analogic would co-brand the devices and reconfigure its Lifegard II monitor to include the Company’s MAXNIBP branded non-invasive blood pressure and other branded technologies. Accordingly, the Company would reimburse Analogic approximately $900,000 upon meeting agreed milestone dates for such efforts. As of June 30, 2009, the Company had made payments to Analogic of $90,000.
On November 24, 2008, Analogic commenced arbitration against the Company contending that the Company breached the Agreement. Analogic was seeking damages of approximately $765,000 for costs it allegedly incurred in performing under the Agreement including
winding down costs and additional remedies which may provide for relief totaling double or treble damages, in addition to attorney fees. The Company denied Analogic’s claims and asserted a counterclaim for damages in excess of those sought by Analogic. The arbitration hearing was conducted on June 15, 2009. The Company has subsequently reached a settlement of its arbitration pursuant to which Analogic has agreed to pay the Company the sum of $811,000 in full satisfaction of all matters raised
in the arbitration. The Company and Analogic have negotiated a conclusion to their contractual relationship by way of an orderly process that will protect the customers of the Company and Analogic by allowing the Company to continue distributing products until July 31, 2010.
On August 7, 2009, Somanetics Corporation filed an action against the Company in the United States District Court for the Eastern District of Michigan alleging patent infringement, false advertising, and common law unfair competition and libel. The complaint
requests injunctive relief and unspecified monetary damages, including treble damages and reasonable attorneys’ fees. The Company is evaluating its response and intends to vigorously defend all claims brought by Somanetics.
The fair value of the Company’s debt as of June 30, 2009 approximates its carrying value of $5,143,063. Fair value was determined using unobservable inputs.
There are no new accounting pronouncements that would materially affect the Company’s financial statements or results of operations for the periods reported herein.
Form 10-Q
June 30, 2009
Page 12 ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Certain statements included in this report, including without limitation statements in the Management’s Discussion and Analysis of Financial Condition and Results of Operations, which are not historical facts, are “forward-looking statements” within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements represent the Company’s current expectations regarding future events. The Company cautions that such statements are qualified by important factors that could cause actual results to differ materially from expected results which may be contained in the forward-looking statements. All forward-looking statements involve risks and uncertainties, including, but not
limited to, the following: foreign currency fluctuations, regulations and other economic and political factors which affect the Company’s ability to market its products internationally, new product introductions by the Company’s competitors, increased price competition, dependence upon significant customers, availability and cost of components for the Company’s products, the impact of any adverse litigation, marketplace acceptance for the Company’s new products, FDA and other
governmental regulatory and enforcement actions, changes to federal research and development grant programs presently utilized by the Company and other factors described in greater detail in the Company’s most recent annual report on Form 10-K.
Results of Operations
Operating results for both the three month and six month periods ended June 30, 2009 have been affected by the worldwide economic downturn and weakened demand for the Company’s products particularly in U.S. markets together with increased Fore-Sight related operating expenses.
For the three months ended June 30, 2009, the Company reported a net loss of $834,000 or ($0.07) per basic and diluted common share compared to a net loss of $32,000 or $0.00 per basic and diluted common share reported for the three months ended June 30, 2008. Shortfalls in revenues of $1,975,000
compared to the prior year second quarter and increased Fore-Sight related operating expenses of approximately $263,000 were primarily responsible for the increased losses. Pre-tax losses for the three-month periods ended June 30, 2009 and 2008 were also affected by approximately $89,000 and $91,000 respectively, of stock compensation expense.
The Company reported a net loss of $1,737,000 or ($0.15) per basic and diluted common share for the six months ended June 30, 2009 compared to a net loss of $562,000 or ($0.05) per basic and diluted common share for first six months of 2008. Revenue shortfalls of $2,530,000 compared to the
first six months of the prior year and increased Fore-Sight related expenses of approximately $815,000 were largely responsible for the increased losses. Pre-tax income for the six-month periods ended June 30, 2009 and 2008 was also affected by $166,000 and $231,000 respectively, of stock compensation expense.
The Company generated revenues of $8,568,000 for the three months ended June 30, 2009, a decrease of $1,975,000 or 19%, compared to revenues of $10,543,000 for the three months ended June 30, 2008. The following table provides information with respect to revenues by major category:
Form 10-Q
June 30, 2009
Page 13 Bedside monitoring product revenues for the three months ended June 30, 2009 decreased $832,000 or 21% to $3,068,000 from $3,900,000 reported for the same three months of the prior year as a result of decreases in sales of vital signs monitors and accessories to certain key U.S. customers
including the Veterans Administration and products sold into the veterinary market under an exclusive private label agreement and sales of co-branded Analogic products outside of the U.S.
Critical care monitoring product revenues of $982,000 represent sales of the Company’s Fore-Sight cerebral oximetry monitors, sensors and accessories. During the second quarter ended June 30, 2009, the Company placed or sold approximately 16 monitors with customers bringing the installed
base of Fore-Sight monitors worldwide to 178 monitors. Under the Company’s monitor placement arrangements, customers are entitled to use the Company’s monitors at no cost in exchange for purchase orders for Fore-Sight sensors.
Blood pressure measurement technology sales of $1,476,000 for the three months ended June 30, 2009 decreased $728,000 or 33% from $2,204,000 reported for the same three months of the prior year. Reduced sales of OEM modules into the international market were primarily responsible for the
decrease. Sales to the Company’s largest OEM customer, Medtronic Physio-Control, were also down and accounted for approximately $282,000 of the sales shortfall during this period.
Supplies and service sales decreased $1,020,000 or 25% to $3,042,000 for the three months ended June 30, 2009 from $4,062,000 for the same three months of the prior year. A reduction in sales of blood pressure cuffs to a significant customer accounted for the entire reduction in sales in
this category.
Sales to the U.S. market accounted for $5,589,000 or 65% of the total revenues reported for the three months ended June 30, 2009, a decrease of $2,141,000 or 28% from the $7,730,000 of sales reported for the three months ended June 30, 2008. Sales in nearly all product categories to the U.S.
market were down with the exception of Fore-Sight monitors and sensors. International sales accounted for $2,979,000 or 35% of the total revenues reported for the three months ended June 30, 2009, an increase of $166,000 or 6% from the $2,813,000 reported for the same period of the prior year. Increases in international sales of Fore-Sight monitors and sensors and bedside monitoring products were largely offset by reduced OEM module sales.
The Company generated revenues of $16,974,000 for the six months ended June 30, 2009, a decrease of $2,530,000 or 13%, compared to revenues of $19,504,000 for the six months ended June 30, 2008. The following table provides information with respect to revenues by major category:
Form 10-Q
June 30, 2009
Page 14 Bedside monitoring product revenues for the six months ended June 30, 2009 decreased $1,764,000 or 24% led by decreases in sales of vital signs monitors to U.S. customers primarily the Veterans Administration, sales into the veterinary market and sales of co-branded Analogic products outside
of the U.S.
Critical care product revenues which represent sales of the Company’s Fore-Sight cerebral oximetry monitors, sensors and accessories, increased $1,217,000 to $1,867,000 for the six months ended June 30, 2009 compared to $650,000 for the same period of the prior year primarily as a result
of increased sensor sales on an expanded installed base. Sales outside of the U.S. accounted for approximately 50% of the increase in overall Fore-Sight sales during this period.
Blood pressure measurement technology sales of $2,959,000 for the six months ended June 30, 2009 decreased $604,000 or 17% from $3,563,000 reported for the same six months of the prior year. Lower sales outside of the U.S. were primarily responsible for the decrease.
Supplies and service sales decreased $1,379,000 or 17% to $6,504,000 for the six months ended June 30, 2009 from $7,883,000 for the same six months of the prior year. Sales of blood pressure cuffs accounted for the entire shortfall in this product category.
Sales to the U.S. market accounted for $11,959,000 or 70% of the total revenues reported for the six months ended June 30, 2009, a decrease of $2,103,000 or 15% from the $14,062,000 in sales reported for the six months ended June 30, 2008. Sales of bedside monitoring products and blood pressure
cuffs sales were largely responsible for the reduction and were partially offset by increased Fore-Sight product sales. International sales accounted for $5,015,000 or 30% of the total revenues reported for the six months ended June 30, 2009, a decrease of $427,000 or 9% from the $5,442,000 reported for the same period of the prior year. Reductions in Analogic product sales and blood pressure cuff sales were partially offset by increased Fore-Sight revenues.
Cost of sales was $5,976,000 or 69.7% of revenues for the three months ended June 30, 2009 compared to $7,051,000 or 66.9% for the same three months of the prior year. Cost of sales for the six months ended June 30, 2009 was $11,916,000 or 70.2% of revenues compared to $13,332,000 or 68.4%
of revenues for the six months ended June 30, 2008. The increase in cost of sales as a percentage of revenues for both periods resulted from unfavorable product and geographical mix, inventory adjustments and unapplied manufacturing overhead costs as a percentage of the reduced revenues for these periods.
Operating expenses for the three months ended June 30, 2009 increased $237,000 or 7% to $3,756,000 from $3,519,000 for the three months ended June 30, 2008. Operating expenses for the first six months of 2009 increased $542,000 or 8% to $7,593,000 from $7,051,000 reported for the same period the prior year. Operating expenses for both
periods include increases in Fore-Sight related spending as well as significant expenditures for legal fees related to the Analogic arbitration matter. Effective May 4, 2009 the Company initiated efforts to reduce expenses and improve cash flows through certain personnel cutbacks, Company-wide wage rate reductions approximating 5% of base pay levels and other benefit adjustments. These reductions are expected to create over $1,000,000 of annualized savings.
Research and development (“R&D”) expenses increased $111,000 or 24% to $578,000 or 7% of revenues for the three months ended June 30, 2009 compared to $467,000 or 4% of revenues for the three months ended June 30, 2008. Increases in Fore-Sight project related expenses partially
offset by increased reimbursements from the National Institutes of Health (“NIH”) pertaining to the Company’s Near-Infrared Spectroscopy (“NIRS”) technology compared to the same period of the prior year were primarily responsible for the increase in net R&D expenses. Increased Fore-Sight related clinical research expenses also contributed to the overall increase in R&D expenses for this period. R&D expenses for the first six months of 2009 increased $226,000 or 23% to
$1,204,000 from $978,000 reported for the first six months of the prior year. Engineering project expenses and clinical expenses were responsible for the increase and were partially offset by increased NIH reimbursements. For the three months and six months ended June 30, 2009, NIH reimbursements totaled $188,000 and $413,000, respectively, compared to $124,000 and $255,000 for the three and six-month periods ended June 30,
2008. As of June 30, 2009, a maximum of approximately $1.4 million remains available under the $2.8 million multi-year NIH award received during 2007.
Form 10-Q
June 30, 2009
Page 15 Selling, general and administrative expenses (“S,G&A”) increased $126,000 or 4% to $3,178,000, or 37% of revenues for the three months ended June 30, 2009 compared to $3,052,000, or 29% of revenues for the three months ended June 30, 2008. Sales and marketing
expenses directly associated with the Fore-Sight cerebral oximetry effort totaled $986,000 and increased approximately $163,000 or 20% over the same three months of the prior year primarily as a result of costs associated with additional field sales and marketing personnel. Other sales and marketing expenses totaled $1,054,000 and decreased $241,000 from the $1,295,000 of expenses reported for the three months ended June 30, 2008. General and administrative expenses increased $204,000 or 22% to $1,138,000
as a result of increased legal expenses related to the Analogic arbitration partially offset by reduced salaries and related benefits.
S,G&A expenses for the first six months of 2009 totaled $6,389,000, an increase of $316,000, or approximately 5%, over the $6,073,000 reported for the first six months of 2008. Fore-Sight related sales and marketing expenses were $2,094,000 and accounted for $595,000 of the increase in
S,G&A expenses. Increases in spending were primarily driven by additional sales and marketing personnel. Other sales and marketing expenses totaled $2,132,000 and decreased approximately $539,000 or 20% from the $2,671,000 reported for the six months ended June 30, 2008. G&A expenses totaled $2,163,000 and increased approximately $260,000 or 14% as a result of increased legal expenses related to the Analogic matter partially offset by reductions in patent related legal fees, salaries and related benefits
and various other expenses including strategic planning costs, recruitment, supplies and stock compensation expense.
Interest expense decreased to $63,000 and $113,000, respectively for the three and six months ended June 30, 2009 compared to $71,000 and $143,000, respectively for the three and six months ended June 30, 2008. The decrease in interest expense resulted primarily from lower
outstanding balances of long-term debt and reduced interest rates on advances under the Company’s line-of-credit.
The income tax benefit of $912,000 for the six months ended June 30, 2009 reflects a combined estimated federal and state effective tax benefit of 36% and varies from the statutory rate as a result of anticipated state and federal R&D tax credits partially offset by non-deductible expenses
including stock compensation expense. The income tax benefit of $461,000 recorded for the six months ended June 30, 2008 reflects a combined estimated federal and state effective tax benefit of 45% and also varies from the statutory rate as a result of anticipated state and federal R&D tax credits partially offset by non-deductible expenses including stock compensation expense.
Financial Condition, Liquidity and Capital Resources
At June 30, 2009, the Company’s cash and cash equivalents totaled $815,000 compared to $1,083,000 at December 31, 2008. Working capital decreased $2,431,000 to $8,388,000 at June 30, 2009, from $10,819,000 on December 31, 2008. The Company’s current ratio decreased
to 2.1 to 1 from 2.9 to 1.
Cash used by operations for the six months ended June 30, 2009 was $1,095,000 compared to cash provided by operations of $335,000 for the first six months of the prior year. Increased operating losses net of depreciation and amortization were partially offset by reductions in inventory and
increases in accounts payable and accrued expenses. The Company has realized inventory reductions over the past twelve months approximating $1,800,000 and expects further reductions for the remainder of 2009.
Cash used in investing activities was $239,000 for the six months ended June 30, 2009 compared to cash used in investing activities of $1,274,000 for the first six months of the prior year. Expenditures for property and equipment during the six months ended June 30, 2008 were driven by increases
in Fore-Sight cerebral oximeter units at customer sites of $575,000 and other purchases of $345,000 largely related to Fore-Sight demonstration equipment, production equipment expenditures required to support Fore-sight sensor manufacturing and increase blood-pressure cuff production capacity as well as various information technology related expenditures.
Form 10-Q
June 30, 2009
Page 16 Cash provided by financing activities for the six months ended June 30, 2009 was $1,066,000 compared to cash provided by financing activities of $1,183,000 for the first six months of the prior year. Borrowings under the line-of-credit agreement during 2009 approximated $1,129,000
and were responsible for the cash provided from financing activities during this period. Cash provided from financing activities for the first six months of the prior year were generated from a private placement of 333,333 shares of its common stock for aggregate proceeds of $1,000,000.
The Company has a line of credit agreement with its bank lender, NewAlliance Bank, which was amended on April 3, 2009 effective March 31, 2009 pursuant to a Second Modification Agreement (as amended, the “Agreement”). In accordance with the Agreement, the maximum availability
was modified from $10,000,000 to $5,000,000 subject to a borrowing base formula equal to the sum of (i) 75% of eligible receivables and (ii) the lesser of $2,500,000 or 30% of eligible inventory. Interest on outstanding amounts is at the Prime Rate plus 1.0% and is subject to a floor of 4.0%. Borrowings are secured by a first priority lien on all the business assets of the Company. The Agreement contains customary non-financial covenants and financial covenants, consisting of a debt service coverage ratio and
a debt to tangible net worth ratio, and expires on July 1, 2010. Under the terms of the Agreement, the debt service coverage ratio was revised from a quarterly test to an annual test for the twelve months ending December 31, 2009 and the minimum ratio revised from 1.5 to 1 to 1.0 to 1. As of the first quarter of 2010 and thereafter, the ratio returns to 1.5 to 1 with testing resumed on a quarterly basis. As of June 30, 2009, there was $3,123,277 outstanding under the Agreement. Borrowing availability is calculated
on a monthly basis and subject to variations based upon the accounts receivable and inventory based formula. A maximum of $5,000,000 is available for borrowing under the formula at June 30, 2009 for the following calendar month.
The Company believes that its sources of funds consisting of cash and cash equivalents and funds available from the line of credit facility will be sufficient to meet its current and expected short-term requirements. However, future cash flows may be impacted by a number of factors, including
changing market conditions or failure to meet financial covenants under our current or any future loan agreement. Changes in payment terms to one or more of our major suppliers could also have a material adverse effect on our results of operations and future liquidity. We believe that our current levels of working capital and available debt financing are insufficient to fund major growth initiatives, such as significant increases in our sales and marketing personnel, or material acquisitions. There can be no
assurance that we will be successful in securing such funding for major initiatives, obtaining a new credit agreement or securing additional sources or forms of capital for major initiatives.
Critical Accounting Policies and Estimates
The Company’s discussion and analysis of financial condition and results of operations are based on the condensed financial statements. The preparation of these financial statements requires the Company to make estimates and judgments that affect the amounts reported in them.
The Company’s critical accounting policies and estimates include those related to revenue recognition, the valuations of inventories and deferred income tax assets, measuring stock compensation, and warranty costs, determining useful lives of intangible assets, and making asset impairment valuations. The Company bases its estimates on historical experience and on various other assumptions that management believes to be reasonable under the circumstances. Actual results may differ from these
estimates under different assumptions or conditions. For additional information about the Company’s critical accounting policies and estimates, see Note 3 to the financial statements included in the Company’s Form 10-K for the year ended December 31, 2008. There were no significant changes in critical accounting policies and estimates during the three months ended June 30, 2009.
Form 10-Q
June 30, 2009
Page 17 ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
The Company has certain exposures to market risk related to changes in interest rates. The Company has an outstanding line-of-credit agreement, under which there were borrowings of $3,123,277 at June 30, 2009. The line-of-credit agreement, amended on April 3, 2009 and
effective as of March 31, 2009, bears interest at variable rates based on prime rate indices. The Company holds no derivative securities for trading purposes and is not subject in any material respect to currency or other commodity risk.
ITEM 4. CONTROLS AND PROCEDURES
The Company maintains disclosure controls and procedures that are designed to ensure that information required to be disclosed in the Company’s Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated
to the Company’s management, including its Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure based on the definition of “disclosure controls and procedures” in Rule 13a-15(e). In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and
procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management necessarily is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.
The Company carried out an evaluation, under the supervision and with the participation of the Company’s management, including the Company’s Chief Executive Officer and the Company’s Chief Financial Officer, of the effectiveness of the design and operation of the Company’s
disclosure controls and procedures as of June 30, 2009. Based upon the foregoing evaluation, the Chief Executive Officer and Chief Financial Officer concluded that the Company’s disclosure controls and procedures were effective as of that date.
There have been no changes in the Company’s internal control over financial reporting during the quarter ended June 30, 2009 that have materially affected, or are reasonably likely to materially affect the Company’s internal control over financial reporting.
Reference is made to the Certifications of the Chief Executive Officer and the Chief Financial Officer about these and other matters attached as Exhibits 31.1, 31.2 and 32.1 to this report.
PART II – OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
The manufacture and sale of our products exposes us to product liability claims and product recalls, including those which may arise from misuse or malfunction of, or design flaws in, our products or use of our products with components or systems not manufactured or sold by us. Product liability claims or product recalls, regardless
of their ultimate outcome, could require us to spend significant time and money in litigation or to pay significant damages. We are currently a defendant in a pending product liability action which may be scheduled for trial during late 200. Although we believe that our product liability insurance is sufficient to cover any damages and costs that are likely with respect to this matter, there can be no assurance that this will be the case with
respect to any future matters. Furthermore, we may not be able to obtain insurance in the future at satisfactory rates or in adequate amounts. In addition, publicity pertaining to the misuse or malfunction of, or design flaws in, our products could impair our ability to successfully market and sell our products and could lead to product recalls.
Form 10-Q
June 30, 2009
Page 18 Analogic Arbitration
On May 8, 2007, the Company signed an exclusive distribution agreement (the “Agreement”) with Analogic Corporation (“Analogic”) under which the Company obtained worldwide exclusive rights to market the Analogic Lifegard® family of non-invasive patient monitors. Under the Agreement, Analogic would co-brand the
devices and reconfigure its Lifegard II monitor to include the Company’s MAXNIBP branded non-invasive blood pressure and other branded technologies. Accordingly, the Company would reimburse Analogic approximately $900,000 upon meeting agreed milestone dates for such efforts. As of June 30, 2009, the Company had made one payment to Analogic of $90,000.
On November 24, 2008, Analogic commenced arbitration against the Company contending that the Company breached the Agreement. Analogic was seeking damages of approximately $765,000 for costs it allegedly incurred in performing under the Agreement including winding down costs and additional remedies which may provide for relief
totaling double or treble damages, in addition to attorney fees. The Company denied Analogic’s claims and asserted a counterclaim for damages in excess of those sought by Analogic. The arbitration hearing was conducted on June 15, 2009. The Company has subsequently reached a settlement of its arbitration pursuant to which Analogic has agreed to pay the Company the sum of $811,000 in full satisfaction of all matters raised
in the arbitration. The Company and Analogic have negotiated a conclusion to their contractual relationship by way of an orderly process that will protect the customers of the Company and Analogic by allowing the Company to continue distributing products until July 31, 2010.
Somanetics Litigation
On August 7, 2009, Somanetics Corporation filed an action against the Company in the United States District Court for the Eastern District of Michigan alleging patent infringement, false advertising, and common law unfair competition and libel. The complaint requests injunctive relief and unspecified monetary damages, including treble
damages and reasonable attorneys’ fees. The Company is evaluating its response and intends to vigorously defend all claims brought by Somanetics.
Other
Furthermore, we may become, in the normal course of our business operations, a party to other legal proceedings in addition to those described in the paragraphs above. None of these other proceedings would be expected to have a material adverse impact on our results of operations, financial condition, or cash flows.
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
At the Company’s annual meeting of stockholders held on June 10, 2009, four proposals were voted upon and approved by the Company’s stockholders. A brief description of each proposal voted upon at the annual meeting and the number of votes cast for, against and withheld, as well as the number of abstentions and broker
non-votes, where applicable, are set forth below.
1) Election of members of the Board of Directors, each for a term of one year
Form 10-Q
June 30, 2009
Page 19 2) Approval of Employee Stock Purchase Plan
3) Amendments to the 2003 Equity Incentive Plan increasing the number of shares issuable under the plan
4) Ratification of the appointment of UHY LLP as auditor for the Company for the fiscal year ending December 31, 2009
ITEM 5. OTHER INFORMATION
On August 10, 2009, the Company entered into an employment agreement with Andrew E. Kersey, Chief Executive Officer. This agreement supersedes Mr. Kersey’s previous agreement dated March 16, 2007 as amended December 29, 2008. Under the terms of the Employment Agreement, Mr. Kersey will
be employed on an “at will” basis, will receive an annual base salary of two hundred fifty thousand dollars ($250,000) and will be eligible for discretionary bonuses. Mr. Kersey will also be entitled to participate in all employee benefit programs of the Company as such programs may be in effect from time to time. If the Company terminates Mr. Kersey’s employment without Serious Cause (as defined in the Employment Agreement) or Mr. Kersey terminates his employment for Good Reason (as defined
in the Employment Agreement), the Company will continue to pay Mr. Kersey his then-current base salary for a period of six (6) months from the date of such termination and he shall be entitled to participate in the Company’s health benefit plans (with standard employee payment not to exceed the payment level prior to termination) for the six (6) month period. In addition, if Mr. Kersey terminates his employment for Good Reason or if the Company terminates Mr. Kersey’s employment without
Serious Cause, all of Mr. Kersey’s equity-linked grants (such as stock options and restricted stock) shall immediately accelerate and vest in full. If Mr. Kersey’s employment is terminated by the Company (or successor thereto) without Serious Cause or Mr. Kersey terminates employment with the Company (or successor thereto) for Good Reason, within the period commencing on the date that a Change of Control (as defined in the Employment Agreement) is formally proposed to the Company’s
Board of Directors and ending on the second anniversary of the date on which such Change of Control occurs, then Mr. Kersey will be entitled to receive his then-current base salary for a period of one (1) year from the date of such termination and in addition will be entitled to participate in the Company’s health benefit plans (with standard employee payment not to exceed the payment level prior to the change in control) for the period of one (1) year. The foregoing description of the Employment
Agreement does not purport to be complete and is qualified in its entirety by reference to the Employment Agreement, a copy of which is filed as Exhibit 10.1 hereto.
Form 10-Q
June 30, 2009
Page 20 On August 10, 2009, the Company entered into an employment agreement (the “Employment Agreement”) with Jeffery A. Baird, Chief Financial Officer. Under the terms of the Employment Agreement, Mr. Baird will be employed on an “at will” basis, will receive an annual
base salary of two hundred thousand dollars ($200,000) and will be eligible for discretionary bonuses. Mr. Baird will also be entitled to participate in all employee benefit programs of the Company as such programs may be in effect from time to time. If the Company terminates Mr. Baird’s employment without Serious Cause (as defined in the Employment Agreement) or Mr. Baird terminates his employment for Good Reason (as defined in the Employment Agreement), the Company will continue to pay Mr. Baird
his then-current base salary for a period of six (6) months from the date of such termination and he shall be entitled to participate in the Company’s health benefit plans (with standard employee payment not to exceed the payment level prior to termination) for the six (6) month period. In addition, if Mr. Baird terminates his employment for Good Reason or if the Company terminates Mr. Baird’s employment without Serious Cause, all of Mr. Baird’s equity-linked grants (such as stock
options and restricted stock) shall immediately accelerate and vest in full. If Mr. Baird’s employment is terminated by the Company (or successor thereto) without Serious Cause or Mr. Baird terminates employment with the Company (or successor thereto) for Good Reason, within the period commencing on the date that a Change of Control (as defined in the Employment Agreement) is formally proposed to the Company’s Board of Directors and ending on the second anniversary of the date on which
such Change of Control occurs, then Mr. Baird will be entitled to receive his then-current base salary for a period of one (1) year from the date of such termination and in addition will be entitled to participate in the Company’s health benefit plans (with standard employee payment not to exceed the payment level prior to the change in control) for the period of one (1) year. The foregoing description of the Employment Agreement does not purport to be complete and is qualified in its entirety
by reference to the Employment Agreement, a copy of which is filed as Exhibit 10.2 hereto.
ITEM 6. EXHIBITS
Form 10-Q
June 30, 2009
Page 21 SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
CAS MEDICAL SYSTEMS, INC.
(Registrant)
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||
